MedTrace Logo

Impedance Cardiography to Decrease the Risk of Preeclampsia

NCT03245970 · Status: WITHDRAWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL

Last updated 2020-08-05

No results posted yet for this study

Summary

To determine if the use of impedance cardiography can identify appropriate medications for use in treating chronic hypertensive patients to decrease the risk of preeclampsia.

Conditions

  • Chronic Hypertension Complicating Pregnancy (Diagnosis)
  • Preeclampsia

Interventions

DRUG

Labetalol Hydrocholoride 200 mg orally every 12 hours

Anti-hypertensive prescribed for increased cardiac output as determined by impedance cardiography

DRUG

Nifedipine 60 mg orally daily

Anti-hypertensive medication prescribed for increased systemic vascular resistance as determined by impedance cardiography

DRUG

Atenolol 25 mg daily

Anti-hypertensive prescribed for increased cardiac output with tachycardia or maternal pulse rate 110 or greater

Sponsors & Collaborators

  • University of Tennessee Medical Center

    lead OTHER

Principal Investigators

  • Kimberly Fortner, MD · University of Tennessee Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
51 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-24
Primary Completion
2020-02-29
Completion
2020-02-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03245970 on ClinicalTrials.gov